Clinical trials: Differentiation
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00054236
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01169363
- Testing
- proteomic profiling, flow cytometry, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Myelodysplastic Syndrome (MDS)
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Study TLK199.2107 is a multicenter, single arm, open-label Phase 2 study of oral ezatiostat (Telintra®) in patients with lenalidomide (Revlimid®) refractory or resistant, red blood cell (RBC) transfusion-dependent, Low to…
- Trial name
- NCT01422486
- Testing
- ezatiostat hydrochloride (Telintra®)
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Telik
Neuroendocrine Carcinoma
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be…
- Trial name
- FOLFIRINEC (NCT04325425)
- Testing
- FOLFOXIRI Protocol, Cisplatin injection
- Where
- 6 sites in France
- Volunteers
- 218 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma
[177Lu]Lu-AKIR001 First-in-human Study
The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in…
- Conditions
- Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma, Cancer Head and Neck, Cervix Carcinoma
- Trial name
- AKIR001 (NCT06639191)
- Testing
- [177Lu]Lu-AKIR001
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Karolinska University Hospital
Bladder Cancer
Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)
This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care.
- Trial name
- METRICS (NCT06721260)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Neuroendocrine Tumors
The MetNET-2 Trial
This is a Pilot, One-arm, Open-label, Prospective Study to evaluate Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with advanced progressive GI or lung carcinoids.
- Trial name
- MetNET-2 (NCT02823691)
- Testing
- Lanreotide and Metformin
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Leukemia
S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899743
- Testing
- polyacrylamide gel electrophoresis, western blotting, immunologic technique
- Volunteers
- 132 people
- Sponsor
- SWOG Cancer Research Network
Thyroid Cancer
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Study rationale High risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation.
- Trial name
- NCT03841617
- Testing
- Thyrogen, I-131, I-124
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1…
- Conditions
- Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06016855
- Testing
- Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Myoclonus, Evoked Potential
Electrophysiological Characteristics and Anatomical Differentiation of Epileptic and Non-epileptic Myoclonus.
This study was conducted on a series of patients with myoclonus to identify the electrophysiological characteristics and the anatomical classification of myoclonus of different causes.
- Trial name
- NCT04235452
- Testing
- Somatosensory evoked potential
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
Lung Nodule
Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation
Investigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT).
- Trial name
- NCT06838806
- Testing
- blood draw
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
TBX3, Cell Differentiation
The Role of TBX3 in Human ES Cell Differentiation
Stem cells can develop into every cell, every tissue and every organ in the human body, e.g., they can make any kind of cells in the human body. Stem cells reproduce themselves many times over and over.
- Trial name
- NCT00581152
- Sponsor
- University of California, Irvine
Breast Cancer, Glioma
Study of the Anti-tumoral Immune Response
This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.
- Trial name
- ERISA (NCT02854644)
- Testing
- additional blood sample
- Where
- France
- Volunteers
- 167 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Differentiated Thyroid Cancer (DTC)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the…
- Trial name
- NCT04940052
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, B-cell
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or…
- Trial name
- NCT03614858
- Testing
- CART-19/22
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Thyroid Cancer
Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)
This research study is to compare the radiopharmacokinetics of I-124 to the radiopharmacokinetics of I-131 in patients who have well-differentiated thyroid cancer after recombinant human thyroid-stimulating hormone (rhTSH)…
- Trial name
- NCT00926978
- Testing
- Radioactive Iodine 124
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Medstar Health Research Institute
Amyotrophic Lateral Sclerosis
sCD163 in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a fatal disease with progressive muscle weakness leading to severe disability and eventually death.Since the diagnosis relies on clinical features and electromyographic abnormalities, which…
- Trial name
- NCT02325375
- Testing
- lumbar puncture for spinal fluid and blood sample
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Neuroendocrine Tumors
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
- Trial name
- NCT03070301
- Testing
- LEE011, everolimus
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Differentiated Thyroid Cancer
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
Primary Objective: To determine the efficacy (as assessed by progression-free survival [PFS]) of vandetanib when compared to placebo in participants with differentiated thyroid cancer that is either locally advanced or metastatic…
- Trial name
- VERIFY (NCT01876784)
- Testing
- Vandetanib (SAR390530)
- Where
- 61 sites in United States, Brazil and 10 more
- Volunteers
- 238 people
- Sponsor
- Genzyme, a Sanofi Company